MCID: PPT001
MIFTS: 45

Peptic Esophagitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Esophagitis

MalaCards integrated aliases for Peptic Esophagitis:

Name: Peptic Esophagitis 12 15 73
Reflux Esophagitis 12 76 15
Gastro-Esophageal Reflux Disease with Esophagitis 73
Peptic Reflux Disease 12
Reflux Oesophagitis 12
Esophagitis, Peptic 44

Classifications:



External Ids:

Disease Ontology 12 DOID:13976
ICD9CM 35 530.11
MeSH 44 D004942
SNOMED-CT 68 54856001 57643001

Summaries for Peptic Esophagitis

MalaCards based summary : Peptic Esophagitis, also known as reflux esophagitis, is related to esophagitis and helicobacter pylori infection. An important gene associated with Peptic Esophagitis is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Legionellosis and Interleukin-10 signaling. The drugs Trimebutine and Rabeprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and lung.

Wikipedia : 76 Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where... more...

Related Diseases for Peptic Esophagitis

Diseases related to Peptic Esophagitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Related Disease Score Top Affiliating Genes
1 esophagitis 30.9 CXCL8 CYP2C19 HRH2 IL1B
2 helicobacter pylori infection 30.6 CXCL8 CYP2C19 IL1B
3 hernia, hiatus 30.6 ATP12A ATP4A CYP2C19
4 gastritis 30.5 CXCL8 HRH2 IL1B
5 bile reflux 30.4 ATP12A ATP4A
6 microinvasive gastric cancer 30.3 ATP12A ATP4A
7 esophagitis, eosinophilic, 1 30.3 ATP12A ATP4A EPC2
8 atrophic gastritis 30.1 CXCL8 IL1B
9 esophageal disease 30.1 ATP12A ATP4A HRH2
10 dyspepsia 30.1 CXCL8 CYP2C19 HRH2
11 esophageal varix 30.0 ATP12A ATP4A
12 superior mesenteric artery syndrome 30.0 ATP12A ATP4A
13 esophageal candidiasis 29.8 ATP12A ATP4A CYP2C19
14 peptic ulcer disease 29.8 ATP4A CXCL8 CYP2C19 HRH2 IL1B
15 celiac disease 1 29.8 ATP12A ATP4A LCT
16 duodenal ulcer 29.8 CXCL8 CYP2C19 HRH2 IL1B
17 gastroesophageal reflux 29.6 CXCL8 CYP2C19 HRH2 IL1B
18 laryngitis 29.6 ATP12A ATP4A HRH2 IL1B
19 gastric ulcer 29.4 CXCL8 CYP2C19 HRH2 IL1B
20 gastrointestinal system disease 29.4 ATP12A ATP4A CXCL8 IL1B
21 gastroparesis 11.5
22 sandifer syndrome 11.2
23 duodenal atresia 11.2
24 adenocarcinoma 10.4
25 gastric cancer 10.2
26 fungal esophagitis 10.2 ATP12A ATP4A
27 diclofenac allergy 10.2 ATP12A ATP4A
28 gastroduodenal crohn's disease 10.2 ATP12A ATP4A
29 neonatal candidiasis 10.2 ATP12A ATP4A
30 photoallergic dermatitis 10.2 ATP12A ATP4A
31 squamous papillomatosis 10.2 ATP12A ATP4A
32 toxic megacolon 10.2 ATP12A ATP4A
33 gastrointestinal neuroendocrine benign tumor 10.2 ATP12A ATP4A
34 gastric antral vascular ectasia 10.2 ATP12A ATP4A
35 granulomatous gastritis 10.2 ATP12A ATP4A
36 gastric neuroendocrine neoplasm 10.2 ATP12A ATP4A
37 acute laryngitis 10.2 ATP12A ATP4A
38 duodenitis 10.2 ATP12A ATP4A
39 rumination disorder 10.2 ATP12A ATP4A
40 congenital disorder of deglycosylation 10.2 ATP12A ATP4A
41 bladder calculus 10.2 ATP12A ATP4A
42 ischemic neuropathy 10.2 ATP12A ATP4A
43 capillary disease 10.2 ATP12A ATP4A
44 dyskinesia of esophagus 10.2 ATP12A ATP4A
45 anismus 10.2 ATP12A ATP4A
46 postsurgical hypothyroidism 10.2 ATP12A ATP4A
47 degos 'en cocarde' erythrokeratoderma 10.2
48 lymphocytic colitis 10.2 ATP12A ATP4A
49 esophageal atresia/tracheoesophageal fistula 10.2 ATP12A ATP4A
50 diarrhea 1, secretory chloride, congenital 10.2 ATP12A ATP4A

Comorbidity relations with Peptic Esophagitis via Phenotypic Disease Network (PDN): (show all 14)


Active Peptic Ulcer Disease Acute Cystitis
Anxiety Bronchitis
Chronic Myocardial Ischemia Deficiency Anemia
Esophageal Disease Esophagitis
Gastroesophageal Reflux Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease

Graphical network of the top 20 diseases related to Peptic Esophagitis:



Diseases related to Peptic Esophagitis

Symptoms & Phenotypes for Peptic Esophagitis

Drugs & Therapeutics for Peptic Esophagitis

Drugs for Peptic Esophagitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trimebutine Approved Phase 4 39133-31-8
2
Rabeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 117976-89-3 5029
3
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 103577-45-3, 138530-94-6 9578005
4
Lansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 103577-45-3 3883
5
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
6
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
7
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
8
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 4594 9579578
9
Zinc Approved, Investigational Phase 4 7440-66-6
10
Maleic acid Experimental Phase 4 110-16-7 444266
11 Rebamipide Investigational Phase 4 90098-04-7
12
Polaprezinc Experimental Phase 4 107667-60-7
13 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Parasympatholytics Phase 4
15 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antacids Phase 4,Phase 3,Phase 2,Phase 1
17 Autonomic Agents Phase 4
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
19 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Omeprazole, sodium bicarbonate drug combination Phase 4
22 Antioxidants Phase 4
23 Protective Agents Phase 4
24 Antiemetics Phase 4
25 Pepsin A Phase 4
26 Dopamine Antagonists Phase 4
27 Dopamine Agents Phase 4
28 Trace Elements Phase 4
29 Micronutrients Phase 4
30
Histamine Approved, Investigational Phase 3,Phase 1 51-45-6, 75614-87-8 774
31
Famotidine Approved Phase 3 76824-35-6 3325
32
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
33
Lafutidine Investigational Phase 3 118288-08-7 5282136
34 Analgesics, Non-Narcotic Phase 3,Phase 1,Phase 2
35 Analgesics Phase 3,Phase 1,Phase 2
36 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
37 Cyclooxygenase Inhibitors Phase 3,Phase 1,Phase 2
38 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 1,Phase 2
39 Antirheumatic Agents Phase 3,Phase 1,Phase 2
40 Histamine Antagonists Phase 3,Phase 1
41
Histamine Phosphate Phase 3,Phase 1 51-74-1 65513
42 Histamine H2 Antagonists Phase 3,Phase 1
43 Antipyretics Phase 3
44 Platelet Aggregation Inhibitors Phase 3
45 Fibrinolytic Agents Phase 3
46
Somatostatin Approved, Investigational Phase 2 51110-01-1, 38916-34-6 53481605
47 lanreotide Approved Phase 2 108736-35-2
48
Piroxicam Approved, Investigational Phase 1, Phase 2 36322-90-4 54676228 5280452
49
Lornoxicam Approved, Investigational Phase 1, Phase 2 70374-39-9 5282204
50
Morphine Approved, Investigational Phase 1, Phase 2 57-27-2 5288826

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole Unknown status NCT02986685 Phase 4 Trimebutine Maleate;rabeprazole
2 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD) Unknown status NCT01110811 Phase 4
5 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
6 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
7 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD Completed NCT01860482 Phase 4 Newrabell® Tablet 10mg
8 Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study Completed NCT00693225 Phase 4 Omeprazole/sodium bicarbonate
9 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
10 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
11 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
12 NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Completed NCT00206180 Phase 4 esomeprazole magnesium (oral medication)
13 Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease Not yet recruiting NCT03467438 Phase 4 Zinc-l-carnosine
14 Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh Unknown status NCT01780285 Phase 3
15 Laparoscopic Lightweight Mesh Repair of Large Hiatal Hernias Unknown status NCT01408108 Phase 3
16 Reflux Esophagitis Phase III Study (Maintenance Treatment) Completed NCT00634114 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
17 Reflux Esophagitis Phase III Study (Initial Treatment) Completed NCT00633932 Phase 3 Esomeprazole;Esomeprazole;Omeprazole
18 Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus) Completed NCT01669811 Phase 3 Esomeprazole (D961H) twice daily;Esomeprazole (D961H) once daily
19 Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis Completed NCT00770913 Phase 2, Phase 3 E3810;E3810;E3810
20 Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - Completed NCT00229424 Phase 3 Lafutidine;Famotidine
21 Sopran - Omeprazole Treatment Versus Surgery Completed NCT00256737 Phase 3 Omeprazole
22 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
23 A Trial of Reconstruction After Distal Gastrectomy for Gastric Cancer Completed NCT01065688 Phase 3
24 Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy Completed NCT00745459 Phase 3 NPO-11
25 Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin Completed NCT01069939 Phase 3 Esomeprazole;Placebo
26 A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer Recruiting NCT03553563 Phase 3 D961H capsule 10mg;D961H sachet 10mg
27 Laparoscopy-assisted Proximal Gastrectomy Versus and Laparoscopy-assisted Total Gastrectomy Terminated NCT01433861 Phase 3
28 Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy Withdrawn NCT00622804 Phase 3
29 Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy Unknown status NCT02054637 Phase 2 Lanreotide
30 The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction After Laparoscopy-assisted Distal Gastrectomy for Gastric Unknown status NCT02694081 Phase 2
31 Continuous Lornoxicam Infusion for Orthopaedic Surgery Unknown status NCT01718756 Phase 1, Phase 2 Placebo;Continuous infusion;Scheduled
32 Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis Completed NCT01538849 Phase 2 Esomeprazole 40mg;YH4808 A mg;YH4808 B mg;YH4808 C mg
33 Pharmacokinetics of Enteral Omeprazole Suspension in Patients With Cerebral Palsy and Mental Retardation Completed NCT00426595 Phase 2 Administration of omeprazole suspension;omeprazole administered as a multi-unit-pellet system
34 Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Active, not recruiting NCT02845986 Phase 2 oxaliplatin
35 Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection Enrolling by invitation NCT03050879 Phase 2 Indocyanine Green Tracer
36 Randomized Controlled Trials on Clinical Outcomes of Totally Laparoscopic Versus Laparoscopy Assisted Total Gastrectomy for Gastric Cancer Enrolling by invitation NCT03006263 Phase 2
37 A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Subjects Aged 1 to 11 Years Suspended NCT02616302 Phase 2 Dexlansoprazole
38 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
39 Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers Completed NCT01599858 Phase 1 YF476;Omeprazole
40 Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers Completed NCT01597674 Phase 1 YF476
41 Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States Completed NCT01538797 Phase 1 YF476;Ranitidine
42 Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men Completed NCT01538784 Phase 1 YF476
43 BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Completed NCT01964131 Phase 1 D961H sachet 20 mg;D961H HPMC capsule 20 mg
44 Incidence of Reflux Esophagitis After Pancreaticoduodenectomy Unknown status NCT01311908
45 Adipokines and the Risk of Reflux Esophagitis Unknown status NCT01560598
46 Immunologic Factors in Reflux Esophagitis and Barrett’s Esophagus Unknown status NCT00155805
47 24 Hour Esophageal and Electrogastrography to Investigate the Mechanism of Reflux Esophagitis Unknown status NCT00154570
48 The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients Unknown status NCT02149914 Not Applicable PPI
49 Oxidative Stress in Intestinal Metaplasia and Metabolic Syndrome Unknown status NCT02695186
50 Drug Use Surveillance of Takecab for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis" Completed NCT03214952 Vonoprazan

Search NIH Clinical Center for Peptic Esophagitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: esophagitis, peptic

Genetic Tests for Peptic Esophagitis

Anatomical Context for Peptic Esophagitis

MalaCards organs/tissues related to Peptic Esophagitis:

41
Testes, Liver, Lung, Skin, Bone, Prostate, Placenta

Publications for Peptic Esophagitis

Articles related to Peptic Esophagitis:

(show top 50) (show all 959)
# Title Authors Year
1
Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors. ( 29435273 )
2018
2
Dichloromethane Extracts of Geranium Koreanum Kom. Alleviates Esophagus Damage in Acute Reflux Esophagitis-Induced Rats by Anti-Inflammatory Activities. ( 30453554 )
2018
3
An update on the latest chemical therapies for reflux esophagitis in children. ( 30496693 )
2018
4
Changes in the Distal Esophageal Microbiota in Chinese Patients with Reflux Esophagitis. ( 30520232 )
2018
5
Melatonin in Prevention of the Sequence from Reflux Esophagitis to Barrett's Esophagus and Esophageal Adenocarcinoma: Experimental and Clinical Perspectives. ( 30011784 )
2018
6
Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study. ( 30038671 )
2018
7
Transabdominal ultrasound elastography of the esophagogastric junction predicts reflux esophagitis. ( 30043241 )
2018
8
Vertical and Circumferential Localization of Esophageal Mucosal Breaks in Patients with Mild Reflux Esophagitis. ( 30101941 )
2018
9
Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. ( 30186929 )
2018
10
Prospective Single Arm Study on the Effect of Ilaprazole in Patients with Heartburn but No Reflux Esophagitis. ( 30187702 )
2018
11
Comparison of Clinical Characteristics of Patients with Acute Esophageal Mucosal Lesion and those with Severe Reflux Esophagitis. ( 30212811 )
2018
12
Impact of reflux esophagitis on the esophageal function before and after laparoscopic fundoplication. ( 30225739 )
2018
13
Linked color imaging improves detection of minimal change esophagitis in non-erosive reflux esophagitis patients. ( 30302374 )
2018
14
An Ethanolic Extract of Allium hookeri Root Alleviates Reflux Esophagitis and Modulates NF-κB Signaling. ( 30402117 )
2018
15
Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis. ( 29514137 )
2018
16
A randomized, double blind, controlled, multi center study of Ilaparazole in the treatment of reflux esophagitis-Phase III clinical trial. ( 29540336 )
2018
17
Leptin Aggravates Reflux Esophagitis by Increasing Tissue Levels of Macrophage Migration Inhibitory Factor in Rats. ( 29760351 )
2018
18
Relevance of histology in the diagnosis of reflux esophagitis. ( 29766511 )
2018
19
Effects of Platycodin D on Reflux Esophagitis due to Modulation of Antioxidant Defense Systems. ( 29770154 )
2018
20
Non-alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study. ( 29131401 )
2018
21
Effect of Low-Dose Aspirin on Chronic Acid Reflux Esophagitis in Rats. ( 29143196 )
2018
22
Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. ( 29188387 )
2018
23
The predictive value of computed tomography in the detection of reflux esophagitis in patients undergoing upper endoscopy. ( 29190519 )
2018
24
Dental and oropharyngeal lesions in rats with chronic acid reflux esophagitis. ( 28882408 )
2017
25
Low-Molecular-Weight Oligonol, a Polyphenol Derived from Lychee Fruit, Attenuates Experimental Reflux Esophagitis and HCl/Ethanol-Induced Gastric Ulcer. ( 29243969 )
2017
26
Risk Factors for Helicobacter pylori Infection and Endoscopic Reflux Esophagitis in Healthy Young Japanese Volunteers. ( 28943553 )
2017
27
Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. ( 28357069 )
2017
28
Anti-apoptotic effect of banhasasim-tang on chronic acid reflux esophagitis. ( 28740353 )
2017
29
Expression of Serum Exosomal and Esophageal MicroRNA in Rat Reflux Esophagitis. ( 28757556 )
2017
30
Associations between reflux esophagitis and the progression of coronary artery calcification: A cohort study. ( 28981523 )
2017
31
Prevalence and Epidemiological Characteristics of Endoscopically Proven Reflux Esophagitis in Children in Korea. ( 29026732 )
2017
32
Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis. ( 29063416 )
2017
33
Relevance between GerdQ score and the severity of reflux esophagitis in Uygur and Han Chinese. ( 29088793 )
2017
34
A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2α: a potential role for targeting HIF-2α to prevent and treat reflux esophagitis. ( 29112883 )
2017
35
Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis. ( 29142181 )
2017
36
Effects of Different Ratio of n-6/n-3 Polyunsaturated Fatty Acids on the PI3K/Akt Pathway in Rats with Reflux Esophagitis. ( 28134235 )
2017
37
Incidence of Biliary Reflux Esophagitis After Laparoscopic Omega Loop Gastric Bypass in Morbidly Obese Patients. ( 28157428 )
2017
38
Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. ( 28190016 )
2017
39
Mucosal breaks show same circumferential distribution in majority of patients with recurrent reflux esophagitis. ( 28317018 )
2017
40
Banhasasim-Tang Treatment Reduces the Severity of Esophageal Mucosal Ulcer on Chronic Acid Reflux Esophagitis in Rats. ( 28349065 )
2017
41
Reflux esophagitis and its role in the pathogenesis of Barrett's metaplasia. ( 28451845 )
2017
42
Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study. ( 28502925 )
2017
43
Impact of the Level of Anastomosis on Reflux Esophagitis Following Esophagectomy with Gastric Tube Reconstruction. ( 27798723 )
2017
44
Different effects of dietary factors on reflux esophagitis and non-erosive reflux disease in 11,690 Korean subjects. ( 27848027 )
2017
45
Similarities and differences among eosinophilic esophagitis, proton-pump inhibitor-responsive esophageal eosinophilia, and reflux esophagitis: comparisons of clinical, endoscopic, and histopathological findings in Japanese patients. ( 27108416 )
2016
46
A Study on the Relationship between Reflux Esophagitis and Periodontitis. ( 27629943 )
2016
47
Decreased n-6/n-3 polyunsaturated fatty acid ratio reduces chronic reflux esophagitis in rats. ( 27637339 )
2016
48
Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. ( 26580676 )
2016
49
A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis. ( 27605258 )
2016
50
Turning the Pathogenesis of Acute Peptic Esophagitis Inside Out. ( 27187299 )
2016

Variations for Peptic Esophagitis

Expression for Peptic Esophagitis

Search GEO for disease gene expression data for Peptic Esophagitis.

Pathways for Peptic Esophagitis

Pathways related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.06 CXCL8 IL1B
2 10.95 CXCL8 IL1B
3 10.85 CXCL8 IL1B
4 10.62 ATP4A HRH2
5 9.32 ATP4A HRH2

GO Terms for Peptic Esophagitis

Biological processes related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium ion import across plasma membrane GO:1990573 9.43 ATP12A ATP4A
2 potassium ion import GO:0010107 9.4 ATP12A ATP4A
3 ATP hydrolysis coupled proton transport GO:0015991 9.37 ATP12A ATP4A
4 positive regulation of neutrophil chemotaxis GO:0090023 9.32 CXCL8 IL1B
5 cellular sodium ion homeostasis GO:0006883 9.26 ATP12A ATP4A
6 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.16 ATP12A ATP4A
7 cellular potassium ion homeostasis GO:0030007 8.96 ATP12A ATP4A
8 sodium ion export across plasma membrane GO:0036376 8.62 ATP12A ATP4A

Molecular functions related to Peptic Esophagitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 8.96 ATP12A ATP4A
2 potassium:proton exchanging ATPase activity GO:0008900 8.62 ATP12A ATP4A

Sources for Peptic Esophagitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....